Melatonin as an anti-inflammatory hormone bridging migraine relief and cancer immunity enhancement: a literature review.

Scientists have discovered that melatonin, the natural hormone that helps regulate sleep, may offer dual benefits for people suffering from migraines while also supporting the body's ability to fight cancer. This comprehensive review examined how melatonin works as an anti-inflammatory agent in the brain and immune system. Researchers found that migraine sufferers often have low melatonin levels before attacks begin, and nightly melatonin supplementation performed as well as standard migraine prevention medications in reducing monthly headache frequency while improving sleep quality. What makes this particularly interesting is that the same inflammatory chemicals involved in migraine attacks—including NF-κB, IL-6, and TNF-α—also weaken the immune system's ability to detect and destroy cancer cells. Melatonin appears to calm these inflammatory pathways in both conditions. In cancer studies, higher doses of melatonin helped reprogram immune cells to better attack tumors and enhanced the effectiveness of immunotherapy treatments. The review suggests melatonin acts as a bridge molecule, reducing migraine-related inflammation while simultaneously strengthening anti-cancer immunity. For acupuncture patients, this is relevant because both acupuncture and melatonin target inflammatory pathways and circadian rhythm regulation. Combining acupuncture treatments with appropriately timed melatonin supplementation may offer complementary benefits for migraine prevention, though more research is needed to establish optimal protocols. The review also highlights promising new delivery methods and timing strategies based on the body's natural rhythms. To explore whether this integrative approach might benefit your migraine management, consult with a qualified, licensed acupuncturist experienced in treating headache disorders.

This literature review establishes melatonin as a pleiotropic immunomodulator bridging migraine prophylaxis and cancer immunotherapy through shared inflammatory pathways. The authors synthesize molecular pharmacology, preclinical models, and early-phase trials demonstrating that endogenous melatonin decline precedes migraine attacks, while nightly supplementation rivals first-line preventives in reducing monthly headache burden and restoring sleep architecture. No specific sample sizes or effect sizes are provided in this review-type article. The mechanistic link centers on melatonin's suppression of NF-κB, NLRP3 inflammasome, IL-6, TNF-α, and ROS—the same "inflammatory genome" that impairs cytotoxic immunity in solid tumors. Supraphysiological melatonin doses reprogram tumor-associated macrophages toward M1 phenotype, amplify granzyme-B from CD8+ T cells, and down-regulate PD-L1 expression, potentially enhancing checkpoint blockade efficacy. Clinical takeaway: Melatonin supplementation may serve dual therapeutic roles for patients presenting with migraines, particularly those with cancer history or concurrent immunotherapy. Integration with acupuncture's anti-inflammatory and circadian-regulating effects warrants investigation through chronobiology-guided protocols combining CGRP pathway modulation.